希美加群
| 中文名称 | 希美加群 |
|---|---|
| 中文同义词 | ((R)-1-环己基-2-((S)-2-((4-(N-羟基氨基甲酰胺基)苄基)氨基甲酰)壬苷-1-基)-2-氧乙基)甘氨酸乙酯;希美加群,10 MM DMSO 溶液;Ximelagatran【CAS:192939-46-1】【规格:2.5mg】;Ximelagatran【CAS：192939-46-1】【规格：2.5mg】 |
| 英文名称 | EXANTA |
| 英文同义词 | N-[(1R)-1-Cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]glycine Ethyl Ester;EXANTA;Glycine, N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyaMino)iMinoMethyl]phenyl]Methyl]aMino]carbonyl]-1-azetidinyl]-2-oxoethyl]-, ethyl ester;Exanta (XiMelagatran);Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxoethyl]Amino]Acetate Ximelagatran;Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxoethyl]Amino]Acetate Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxo-Ethyl;XIMELEGATRAN;EXANTA/XIMELEGATRAN |
| CAS号 | 192939-46-1 |
| 分子式 | C24H35N5O5 |
| 分子量 | 473.57 |
| EINECS号 | |
| 相关类别 | 库存;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Aromatics Compounds;Pharmaceuticals |
| Mol文件 | 192939-46-1.mol |
| 结构式 |  |
希美加群 性质
| 熔点 | 65-68C |
|---|---|
| 密度 | 1.35±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | DMSO : 250 mg/mL (527.91 mM; 需要超声波) 甲醇 : 62.5 mg/mL (131.98 mM; 需要超声波) |
| 形态 | 粉末 |
| 酸度系数(pKa) | 6.87±0.69(Predicted) |
| 颜色 | 白色至米色 |
| 稳定性 | 吸湿性 |
| InChIKey | PMOVWDINZOACJB-RBBKRZOGSA-N |
| SMILES | C(OCC)(=O)CN[C@H](C1CCCCC1)C(N1CC[C@H]1C(NCC1=CC=C(C=NNO)C=C1)=O)=O |
Ximelagatran (H 376/95) 是一种口服活性凝血酶抑制剂，可选择性和竞争性地抑制游离和凝块结合的凝血酶。Ximelagatran 还是一种抗凝药物，具有快速起效的抗凝作用，可预测的，剂量依赖性的药代动力学和药效学。
Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran, a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement.
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-10787 | 希美加群 Ximelagatran | 192939-46-1 | 500 μg | 650元 |
| 2026/06/05 | HY-10787 | 希美加群 Ximelagatran | 192939-46-1 | 1 mg | 750元 |